Two-Year Follow-Up Of Pretreatment Anti-Mullerian Hormone (Amh) To Predict For Resumption Of Mense After Chemotherapy In Premenopausal Hormone-Receptor (Hr Plus ) Positive Early Breast Cancer (Ebc).

e12511Background: Menses status is commonly used to measure ovarian function after chemotherapy, but its retrospective pattern limits the prospective application in endocrine therapy plan making of hormone receptor-positive (HR+) early breast cancer (eBC). We reported that prechemothearpy anti-mullerian hormone (AMH) was associated with the one-year resumption of menses in 2016 (ASCO abstract e12032). Here, we present the data of two-year follow-up. Methods: Between August 2013 and December 2014, 120 premenopausal patients younger than 50 years old with HR+ eBC were included retrospectively. We tested the relationship between prechemotherapy AMH, follicle-stimulating hormone (FSH) and estrogen (E) with two-year menses status. Results: After a median follow up of 1074 days (range, 182-1502 days) after chemotherapy, 54 patients (45%) experienced resumption of menses in two-year after chemotherapy. Pretreatment AMH was significantly lower in women with amenorrhoea than those with menses at two-year (0.68±0.9...